as of 08-13-2026 4:00pm EST
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | ARLINGTON |
| Market Cap: | 667.0M | IPO Year: | 2015 |
| Target Price: | $7.93 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | -525.93 |
| 52 Week Low/High: | $2.10 - $10.08 | Next Earning Date: | 05-07-2026 |
| Revenue: | $907,957,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 33.89% | Revenue Growth (next year): | 15.84% |
| P/E Ratio: | -8.51 | Index: | N/A |
| Free Cash Flow: | 3.3M | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SEC 8-K filings with transcript text
May 7, 2026 · 100% conf.
1D
-11.43%
$3.78
Act: -0.82%
5D
-16.78%
$3.55
Act: -3.98%
20D
-16.60%
$3.56
Act: -1.17%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784333678.ccacfa97
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Feb 24, 2026 · 100% conf.
1D
-11.43%
$2.27
Act: +23.83%
5D
-16.78%
$2.13
Act: +37.11%
20D
-16.60%
$2.14
evh-202602240001628908false00016289082026-02-242026-02-24
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
February 24, 2026 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 24, 2026, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended December 31, 2025, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description 99.1 Press Release of Evolent Health, Inc. dated February 24, 2026.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: February 24, 2026
Nov 6, 2025
evh-202511060001628908false00016289082025-11-062025-11-06
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
November 6, 2025 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On November 6, 2025, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 6, 2025, the Company announced a restructuring of leadership roles and transitions of its leadership team.
Chief Financial Officer Transition
On November 6, 2025, the Board of Directors (the “Board”) of the Company appointed Mario Ramos, 54, as the Company’s Chief Financial Officer (principal financial officer), effective January 1, 2026 (the “Effective Date”).
Mr. Ramos served as the Chief Financial Officer of WellBe Senior Medical from October 2024 through October 2025. From June 2022 through June 2024, Mr. Ramos served as the Chief Executive Officer of RWA Wealth Partners, from December 2021 through May 2022, Mr. Ramos served as the Chief Financial Officer of Evolv Technology Holdings, Inc., and from April 2019 through November 2021, Mr. Ramos served as the Chief Financial Officer and Chief Risk Officer of Edelman Financial Engines. From 2011 through 2019, he served as the Chief Financial Officer of CVS Caremark and held other senior roles at CVS Health. Prior to joining CVS Health, Mr. Ramos held investment banking roles at a number of financial institutions. Mr. Ramos holds an MBA from the College of William and Mary and a B.A. in Economics from the University of Richmond.
In connection with Mr. Ramos’s appointment as Chief Financial Officer, the Compensation Committee of the Board set Mr. Ramos’s annual base salary at $550,000, with a variable, at risk maximum cash bonus opportunity of $625,000 under the Company’s anticipated 2026 Bonus Plan, based on performance goals, subject to the discretion of the Compensation Committee. Mr. Ramos will receive a sign-on bonus of $100,000 on the Effective Date, subject to clawback if he resigns or his employment is terminated by the Company for cause within 24 months after the Effective Date. Mr. Ramo
Aug 7, 2025
evh-202508070001628908false00016289082025-08-072025-08-07
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
August 7, 2025 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On August 7, 2025, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description 99.1 Press Release of Evolent Health, Inc. dated August 7, 2025.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: August 7, 2025
May 8, 2025
evh-202505080001628908false00016289082025-05-082025-05-08
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
May 8, 2025 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On May 8, 2025, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2025, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description 99.1 Press Release of Evolent Health, Inc. dated May 8, 2025.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: May 8, 2025
Feb 20, 2025
evh-202502200001628908false00016289082025-02-202025-02-20
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
February 20, 2025 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 20, 2025, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2024, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated February 20, 2025.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: February 20, 2025
Nov 7, 2024
evh-202411070001628908false00016289082024-11-072024-11-07
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
November 7, 2024 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On November 7, 2024, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2024, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated November 7, 2024.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: November 7, 2024
Aug 8, 2024
evh-202408080001628908false00016289082024-08-082024-08-08
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
August 8, 2024 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On August 8, 2024, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2024, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated August 8, 2024.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: August 8, 2024
May 9, 2024
evh-202405090001628908false00016289082024-05-092024-05-09
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
May 9, 2024 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On May 9, 2024, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated May 9, 2024.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: May 9, 2024
Feb 22, 2024
evh-202402220001628908false00016289082024-02-222024-02-22
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
February 22, 2024 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 22, 2024, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2023, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated February 22, 2024.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: February 22, 2024
Jan 8, 2024
evh-20240108January 8, 20240001628908false00016289082024-01-082024-01-08
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
January 8, 2024 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number:(I.R.S. Employer Identification No.)
1812 N. Moore Street,Suite 1705,Arlington,Virginia,22209 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition
On January 9, 2024, Evolent Health, Inc. (the “Company”) will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference. In connection with this presentation and investor meetings, the Company is reaffirming previously issued revenue and Adjusted EBITDA guidance for the three months and year ended December 31, 2023 and announces two new revenue contracts for its technology and services suite, including a new partner logo in the Southwest and the cross-sell of NIA services to a legacy Evolent client in the northeast. Because the Company’s financial statements for the year ended December 31, 2023, have not been finalized or audited, these preliminary statements regarding the Company’s estimated full-year revenue and Adjusted EBITDA are subject to change and the Company’s actual results as of the end of this period may differ materially from these preliminary statements. Accordingly, you should not place undue reliance on these preliminary statements.
Item 7.01. Regulation FD Disclosure
The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.
A copy of the investor presentation materials for the Company’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference is furnished as Exhibit 99.1 and is incorporated herein by reference. The Company may use this updated corporate presentation in meetings with investors from time to time as well.
The information furnished under Items 2.02 and 7.01 of this Report, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description 99.1 Investor Presentation
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: January 8, 2024
Nov 2, 2023
evh-202311020001628908false00016289082023-11-022023-11-02
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
November 2, 2023 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On November 2, 2023, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2023, a copy of which is furnished herewith as Exhibit 99.1. The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated November 2, 2023.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: November 2, 2023
Aug 2, 2023
evh-202308020001628908false00016289082023-08-022023-08-02
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
August 2, 2023 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On August 2, 2023, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2023, a copy of which is furnished herewith as Exhibit 99.1. The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 8.01. Other Events
Evolent Health, Inc. (the “Company”) issued a notice of redemption to the holders of its outstanding 3.50% Convertible Senior Notes due 2024 (the “Notes”) on August 2, 2023, pursuant to which it will redeem the outstanding Notes for cash at a price of 100% of the principal amount of the Notes, plus accrued and unpaid interest, if any, on October 13, 2023 (the “Redemption Date”). Prior to the Redemption Date, the holders of the Notes are entitled to convert to shares of the Company’s Class A Common Stock, par value $0.01 per share (the “Common Stock”) at a rate of 54.8667 shares per $1,000 principal amount of Notes. In the event any holder delivers a conversion notice as provided in that certain Indenture dated as of August 19, 2020 (the “Indenture”) related to the Notes, the Company intends to satisfy its conversion obligation with respect to each $1,000 principal amount of Notes tendered by Physical Settlement (as defined in the Indenture). In the event such conversion would result in a fractional share of Common Stock, an amount in lieu of the fractional share based on the Daily VWAP (as defined in the Indenture) of the Common Stock on the conversion date will be paid in cash by the Company as provided in the Indenture. As of August 2, 2023, $24.3 million aggregate principal amount of the Notes is outstanding. The Company intends to fund the aggregate redemption price using cash on hand.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated August 2, 2023.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:G
May 3, 2023
evh-202305030001628908false00016289082023-05-032023-05-03
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
May 3, 2023 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On May 3, 2023, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2023, a copy of which is furnished herewith as Exhibit 99.1. The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 5.02 - Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) In connection with organizational restructuring, the Company is announcing the departure of Steve Tutewohl, Chief Operating Officer. Mr. Tutewohl’s departure, effective July 3, 2023, will be treated as an involuntary termination without cause consistent with his existing severance and change-in-control agreement, a form of which was filed as Exhibit 10.32 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), on February 26, 2021. Mr. Tutewohl will enter into a customary release of claims. The severance benefits he is entitled to are consistent with a termination without cause, as further described under the heading “Compensation Discussion and Analysis – Potential Payments Upon Termination or Change in Control” in the Company’s definitive proxy statement on Schedule 14A filed with the SEC on April 28, 2023, except that in lieu of a lump sum cash bonus, Mr. Tutewohl and the Company have agreed that he will receive shares of the Company’s Class A common stock in an amount equal to such lump sum cash bonus, calculated based on the closing price of the Company’s Class A common stock on the business day prior to the effective date of his departure. (c) On May 3, 2023, the Company’s Board of Directors appointed Emily Rafferty to serve as the Company’s Chief Operating Officer, effective July 3, 2023. Ms. Rafferty, 40, has served as the President and Chief Operating Officer of Evolent Health Services, a former reporting segment of the Company which houses the Company’s administrative simplification solution and certain supporting population health infrastructure since September 2020. Prior to becoming President and Chief Operating Officer of Evolent Health Services, Ms. Rafferty held multiple leadership roles within the Com
Feb 22, 2023
evh-202302220001628908false00016289082023-02-222023-02-22
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
February 22, 2023 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On February 22, 2023, the Company issued a press release announcing its financial results for the quarter and year ended December 31, 2022, a copy of which is furnished herewith as Exhibit 99.1. The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated February 22, 2023.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: February 22, 2023
Jan 11, 2023
evh-20230111January 11, 20230001628908false00016289082023-01-112023-01-11
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
January 11, 2023 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number:(I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition
On January 11, 2023, the Company will be presenting at the 41st Annual J.P. Morgan Healthcare Conference. In connection with this presentation and investor meetings, the Company is reaffirming previously issued revenue and Adjusted EBITDA guidance for the year ended December 31, 2022.
Because the Company’s financial statements for the year ended December 31, 2022 have not been finalized or audited, these preliminary statements regarding the Company’s estimated full-year revenue and Adjusted EBITDA are subject to change and the Company’s actual results as of the end of this period may differ materially from these preliminary statements. Accordingly, you should not place undue reliance on these preliminary statements.
Item 7.01. Regulation FD Disclosure
The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.
A copy of the investor presentation materials for the Company’s presentation at the 41st Annual J.P. Morgan Healthcare Conference is furnished as Exhibit 99.1 and is incorporated herein by reference. The Company may use this updated corporate presentation in meetings with investors from time to time as well.
The information furnished under Items 2.02 and 7.01 of this Report, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description 99.1 Investor Presentation
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: January 11, 2023
Nov 2, 2022
evh-202211020001628908false00016289082022-11-022022-11-02
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
November 2, 2022 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition On November 2, 2022, the Company issued a press release announcing its financial results for the quarter ended September 30, 2022, a copy of which is furnished herewith as Exhibit 99.1. The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release of Evolent Health, Inc. dated November 2, 2022.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: November 2, 2022
Aug 2, 2022
evh-202208010001628908false00016289082022-08-012022-08-01
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
August 1, 2022 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement. Credit Agreement, Security Agreement and Guarantee Agreement On August 1, 2022, Evolent Health, Inc. (the “Company”) consummated the transactions (the “Closing”) contemplated by the previously announced Agreement and Plan of Merger (the “Merger Agreement”), dated June 24, 2022, by and among the Company, Evolent Health LLC, Endzone Merger Sub, Inc., TPG Growth Iceman Parent, Inc. (“TPG Growth Iceman Parent”), and TPG Growth V Iceman, L.P., solely in its capacity as representative as set forth therein. On August 1, 2022 (the “Closing Date”), the Company entered into a Credit Agreement, by and among the Company, Evolent Health LLC (“Evolent”), Endzone Merger Sub, Inc. (“Endzone” or “Initial Borrower”), which upon consummation of the Closing will be merged with and into TPG Growth Iceman Parent, Implantable Provider Group, Inc. (“Implantable”, collectively with Evolent, Endzone and TPG Growth Iceman Parent, the “Borrowers” and each a “Borrower”), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as collateral agent and as revolver agent (the “Credit Agreement”), pursuant to which the lenders agreed to extend credit to the Borrowers in the form of (i) an initial term loan in the aggregate principal amount of $175.0 million (the “Initial Term Loan Facility”) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0 million, to be determined by reference to the lesser of $50.0 million and a borrowing base (the “Revolving Facility” and, together with the Initial Term Loan Facility, the “Credit Facilities”), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the “Initial Term Loan”), and also borrowed $50.0 million under the Revolving Facility on the Closing Date. In connection with the Credit Agreement, on August 1, 2022, the Company entered into a Security Agreement, by and among the Company, the Borrowers, the other guarantors and the collateral agent for the benefit of the secured parties (the “Security Agreement”), and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties (the “Guarantee Agreement”). Use of Proceeds. The proceeds of the Initial Term Loan may be used to fund ongoing working capital needs and other growth capital expenditure investments, and to finance the transactions contemplated by the Merger Agreement and fund fees and expenses incurred in connection therewith. The proceeds of the Revolving Facility may be used to finance the transactions contemplated by
May 4, 2022
evh-20220504May 4, 20220001628908false00016289082022-05-042022-05-04
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
May 4, 2022 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On May 4, 2022, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2022, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No.Description 99.1 Press Release dated May 4, 2022, announcing Evolent Health, Inc.'s financial results for the quarter ended March 31, 2022.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: May 4, 2022
Feb 23, 2022
evh-20220223February 23, 20220001628908false00016289082022-02-232022-02-23
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
February 23, 2022 Date of Report (Date of earliest event reported)
Evolent Health, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3741532-0454912 (State or other jurisdiction of incorporation or organization)Commission File Number: (I.R.S. Employer Identification No.)
800 N. Glebe Road,Suite 500,Arlington,Virginia,22203 (Address of principal executive offices)(zip code)
(571) 389-6000 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 23, 2022, Evolent Health, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2021, a copy of which is furnished herewith as Exhibit 99.1.
The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No.Description 99.1 Press Release dated February 23, 2022, announcing Evolent Health, Inc.'s financial results for the quarter and year ended December 31, 2021.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Jonathan D. Weinberg Name:Jonathan D. Weinberg Title:General Counsel and Secretary
Date: February 23, 2022
See how EVH stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "EVH Evolent Health Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.